Tivic Health Systems, Inc. (TIVC) Prices 3M Share IPO at $5/sh

Tivic Health Systems, Inc. (Nasdaq: TIVC), a commercial-phase bioelectronic medicine company, today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $15,000,000, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 450,000 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount. All of the shares of common stock are being offered by the Company.

The Company intends to use the proceeds for initiatives to grow sales of its ClearUP® Sinus Relief ("ClearUP") device, including expanding advertising and public relations, growing social media presence, upgrading and optimizing ecommerce infrastructure, online/website design and branding, and other programs to grow awareness of ClearUP. To continue to position Tivic as a trusted brand for evidence-based therapies based on bioelectronic medicine, the Company also plans to expand its clinical research and development activities to identify and validate new product candidates, move them through pre-clinical and clinical development, and develop go-to-market strategies. Additionally, the Company intends to use proceeds to support the launch of the next generation of ClearUP, ClearUP Gen 2, and plans to use the balance for general working capital. Although the Company, from time to time, evaluates potential strategic investments and acquisitions, it does not have any definitive agreements in place to make any such acquisitions at this current time.

Tivic's common stock is expected to begin trading on the Nasdaq Capital Market on November 11, 2021 under the symbol "TIVC." The offering is expected to close on November 15, 2021, subject to satisfaction of customary closing conditions.

ThinkEquity is acting as sole book-running manager for the offering.

A registration statement on Form S-1 (File No. 333-258411) relating to the shares was filed with the Securities and Exchange Commission ("SEC") and became effective on November 10, 2021. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at [email protected]. The final prospectus will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• RenovoRx regains Nasdaq minimum bid price compliance
• Kairos Pharma announces 1-for-7 reverse stock split